Sanofi data supports Ambien use for up to six months

By Elaine Rigoli

Tampa, Fla., July 12 - Sanofi-Aventis said new study results suggest that Ambien CR is well-tolerated and effective in improving sleep onset and maintenance for up to six months in patients with chronic primary insomnia when taken as needed for up to seven nights per week, without rebound insomnia following discontinuation.

According to the data, Ambien CR demonstrated significant improvements in total sleep time, sleep onset latency, wake time after sleep onset, sleep quality and number of awakenings versus a placebo.

This data is important for patients who experience chronic insomnia because it demonstrates that Ambien CR can be taken safely and effectively as needed long-term to help them both fall asleep and maintain sleep through the night, officials noted.

Sanofi-Aventis is a Paris-based pharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.